Drug Trial Radar · NCT06026501
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Aug 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai HyaMab Biotech Co.,Ltd.
- First posted
- Sep 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w).
Conditions
- Advanced Solid Tumors
Interventions
PE0116,PE0105Drug
1. PE0116: 4-1BB Agonist Antibody Drug 2. PE0105: PD-1 Monoclonal Antibody Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicities evaluated by NCI-CTCAE v5.0Time frame: From time of first dose to 21 days after the first dose.
- Adverse events evaluated by NCI CTCAE v5.0Time frame: From time of first dose to 90 days after the last dose.
- Recommended Phase 2 DoseTime frame: From time of first dose of the first patient to the last dose of the last patient in phase 1b..
- Objective response rateTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.